Table 1.
Clinical Characteristics of 281 Patients with Acute Myeloid Leukemia with or without DNMT3A Mutations.*
| Variable | No DNMT3A Mutation (N = 219) |
R882 DNMT3A Mutation (N = 37) |
Non-R882 DNMT3A Mutation (N = 25) |
Any DNMT3A Mutation (N = 62) |
P Value† |
|---|---|---|---|---|---|
| Age at study entry — yr | 47.8±16.6 | 52.1±13.1 | 54.6±14.8 | 53.1±13.7 | 0.02‡ |
| Race — no. (%)§ | 0.58¶ | ||||
| White | 195 (89) | 34 (92) | 21 (84) | 55 (89) | |
| Black | 18 (8) | 2 (5) | 2 (8) | 4 (6) | |
| Other | 6 (3) | 1 (3) | 2 (8) | 3 (5) | |
| Male sex — no. (%) | 125 (57) | 17 (46) | 11 (44) | 28 (45) | 0.10∥ |
| Bone marrow blasts at diagnosis — % | 69.4±18.6 | 73.5±16.3 | 63.6±18.0 | 69.5±17.6 | 0.96‡ |
| Normal karyotype — no./total no. (%) | 76/216 (35) | 27/36 (75) | 17/25 (68) | 44/61 (72) | <0.001∥ |
| White-cell count at diagnosis — (×10−3/mm3) | <0.001** | ||||
| No. of patients | 142 | 27 | 18 | 45 | |
| Mean | 39.3±65.8 | 78.0±57.3 | 29.8±29.4 | 58.7±53.3 | |
| Median | 11.8 | 72.6 | 19.2 | 46.4 | |
| Cytogenetic risk — no./total no. (%)†† | <0.001¶ | ||||
| Favorable | 79/215 (37) | 0/36 | 0/24 | 0/60 | |
| Intermediate | 110/215 (51) | 34/36 (94) | 22/24 (92) | 56/60 (93) | |
| Adverse | 26/215 (12) | 2/36 (6) | 2/24 (8) | 4/60 (7) | |
| AML subtype — no. (%) | |||||
| M3 | 47 (21) | 1 (3) | 0 | 1 (2) | <0.001∥ |
| M4 | 41 (19) | 14 (38) | 6 (24) | 20 (32) | 0.02∥ |
| M5 | 9 (4) | 9 (24) | 3 (12) | 12 (19) | <0.001¶ |
| Mutation — no./total no. (%) | |||||
| NPM1 | 27/216 (13) | 24/37 (65) | 13/25 (52) | 37/62 (60) | <0.001∥ |
| FLT3 | 48/217 (22) | 17/36 (47) | 8/25 (32) | 25/61 (41) | 0.003∥ |
| IDH1 | 12/218 (6) | 10/37 (27) | 3/25 (12) | 13/62 (21) | <0.001∥ |
| IDH2 | 13/217 (6) | 1/37 (3) | 6/25 (24) | 7/62 (11) | 0.15∥ |
| t(15;17) | 45/219 (21) | 0/37 | 0/25 | 0/62 | <0.001∥ |
| t(8;21) | 12/219 (5) | 0/37 | 0/25 | 0/62 | 0.07¶ |
| inv(16) | 20/219 (9) | 0/37 | 0/25 | 0/62 | 0.01¶ |
*
Plus–minus values are means ±SD. DNMT denotes DNA methyltransferase.
†
P values are for the comparisons between no DNMT3A mutations and any DNMT3A mutation.
‡
The P value was calculated by means of Student’s t-test.
§
Race was self-reported.
¶
The P value was calculated by means of Fisher’s exact test.
∥
The P value was calculated by means of Pearson’s chi-square test.
**
The P value was calculated by means of the Wilcoxon test.
††
The Cancer and Leukemia Group B classification system was used to stratify risk on the basis of cytogenetic findings.16